<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852928</url>
  </required_header>
  <id_info>
    <org_study_id>chILD-EU</org_study_id>
    <nct_id>NCT02852928</nct_id>
  </id_info>
  <brief_title>European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank</brief_title>
  <acronym>chILD-EU</acronym>
  <official_title>Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generation of a common European database and biobank Continous assessment and implementation&#xD;
      of guidelines and treatment protocols Establishment of a large observational cohort of chILD&#xD;
      patients Determination the value of outcomes used in child Assess treatment variations used,&#xD;
      deliver data from defined protocols and linked outcomes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective 1: Generation of a common European database and biobank. The existing national&#xD;
      programmes to collect data on chILD in three countries (France, Germany, UK) will enable the&#xD;
      consortium to swiftly adapt current frameworks to a functionally appropriate pan-European&#xD;
      web-based database and biobank. Importantly, compatibility with ongoing United States chILD&#xD;
      data base developments will be factored in.&#xD;
&#xD;
      Objective 2: Continuous assessment and implementation of guidelines and treatment protocols.&#xD;
      Our Standards Working Group will convene regularly. Initial tasks will establish (a) specific&#xD;
      diagnostic pathways, including detailed protocols for gathering clinical information, blood&#xD;
      testing, imaging and pathology (&quot;Best Practice Checklist&quot;); (b) international panels of&#xD;
      clinicians, geneticists, radiologists and pathologists who will review every diagnosis to&#xD;
      quality control the data; and (c) detailed protocols for follow up to generate natural&#xD;
      history data.&#xD;
&#xD;
      Objective 3: Recruitment of a carefully characterized cohort of chILD patients. European wide&#xD;
      recruitment and interdisciplinary critical peer review of all diagnoses submitted from across&#xD;
      Europe is imperative. Each case will be given a diagnosis independently; if no firm diagnosis&#xD;
      is possible, we will review the case periodically as new information becomes available.&#xD;
      During the first year of the study, clinicians´ decisions according to local practice and&#xD;
      outcomes will be independently monitored and assessed.&#xD;
&#xD;
      Objective 4: Determine the value of outcomes used in chILD. We will systematically optimize&#xD;
      and clarify the relative weight of a large spectrum of single and composite clinical outcomes&#xD;
      (using both clinician and carer scoring), sequential limited chest CT (to minimise radiation&#xD;
      exposure), lung function testing, histopathological categorization of lung biopsies, serum&#xD;
      markers and genetic tests. Variability, reproducibility and the effects of training on&#xD;
      reading images will be investigated.&#xD;
&#xD;
      Objective 5: Assess treatment variations used, deliver data from defined protocols and linked&#xD;
      outcomes. This project will analyse in detail treatment and outcomes within and between&#xD;
      subjects using data collected. Analysis of the collected data will enable us to support the&#xD;
      definition of trial protocols planned in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Included subjects with specific diagnosis</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survial</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <condition>Pulmonary Eosinophilia</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Child</condition>
  <eligibility>
    <study_pop>
      <textblock>
        400 prevalent patients with childhood interstitial lung disease (chILD) in Europe 100&#xD;
        incident chILD cases per year&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all children with suspected or&#xD;
&#xD;
          -  verified diagnosis of ILD or&#xD;
&#xD;
          -  masquerading as ILD and&#xD;
&#xD;
          -  those with rare localized parenchymal lung diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other indication as inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universität München, Dr. von Haunersches Kinderspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Cunningham, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Griese, Prof.</last_name>
    <phone>+49/89/440057871</phone>
    <email>Matthias.Griese@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meike Hengst, Dr. med.</last_name>
    <phone>+49/89/440057878</phone>
    <email>Meike.Hengst@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université Pierre et Marie Curie</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annick Clement, Prof</last_name>
      <phone>+33-1 44 73 66 68</phone>
      <email>annick.clement@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Schwerk, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
      <email>schwerk.nicolaus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wetzke, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Snijders, Dr</last_name>
      <phone>+39 049 821 8015</phone>
      <email>deborah.snijders@sanita.padova.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe University, Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <state>Sihhiye</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nural Kiper, Prof</last_name>
      <phone>+903123051224</phone>
      <email>nkiper@hacettepe.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Nagehan Emiralioglu, Dr.</last_name>
      <phone>+903123051334</phone>
      <email>nagehan.emiralioglu@hacettepe.edu.tr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Cuningham, Dr.</last_name>
      <phone>+441315360640</phone>
      <email>steve.cunningham@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Morag MaClean</last_name>
      <phone>+44131 537 3846 / 3878</phone>
      <email>chILD-UK@ed.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://childeu.net</url>
    <description>chILD-EU project website</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>ILD; chILD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

